Novartis India Names Gowree Gokhale Independent Director
Novartis India Limited has appointed Gowree Gokhale as a Non-Executive and Independent Director for a five-year term, with shareholders overwhelmingly approving the move.
Read MoreHealthcare/Biotech News
Zydus Lifesciences Board Approves ₹1100 Crore Share Buyback at ₹1150 Premium
Zydus Lifesciences Limited's Board of Directors has approved a significant share buyback program, signalling a substantial capital return to shareholders. The company plans to repurchase up to 95.65 lakh equity shares, representing 0.95%...
Read More
Zydus Lifesciences Reports 16% Q4 Revenue Growth, Approves Buyback and US Deal
Zydus Lifesciences reported robust Q4 FY26 results with 16% YoY revenue growth to ₹75,870 million and a 20% EBITDA jump. The company announced a ₹11,000 million share buyback and a 100% dividend. A strategic acquisition of US-based Asser...
Read More
Zydus Lifesciences Q4 FY26 Profit Up 8.7%; Approves ₹11,000 Cr Buyback, US Buy
Zydus Lifesciences reported robust Q4 FY26 results with total income up 16.2% YoY to ₹75,870 million and net profit growing 8.7% to ₹12,725 million. The company also announced a substantial ₹11,000 million share buyback and the acquisiti...
Read More
Zydus Lifesciences Reappoints Patel as MD, Adds Lalbhai to Board
Zydus Lifesciences' board reappointed Dr. Sharvil Patel as Managing Director for five years, ensuring leadership continuity. The company also appointed Kulin S. Lalbhai, formerly of Arvind Ltd, as an Additional and Independent Director f...
Read More
Zydus Lifesciences: Profit ₹1,272 Cr, Revenue Up 16%, Debt Soars
Zydus Lifesciences reported strong Q4 and full-year FY26 results, with revenue jumping over 16%. While a clean audit and proposed dividend please shareholders, a sharp rise in borrowings to over ₹8,500 Cr and major one-time costs from le...
Read More
Piramal Pharma Schedules Investor Meetings for Late May to Early June 2026
Piramal Pharma Ltd will host analysts and institutional investors in late May and early June 2026. The scheduled meetings include participation from major global and Indian financial firms, offering a platform for the company to discuss...
Read More
HealthCare Global Opens New Bengaluru Cancer Hospital for ₹129 Cr
HealthCare Global Enterprises Ltd has launched a new 132-bed cancer hospital in Hebbal, North Bengaluru, with an investment of ₹129 crore. The facility aims to provide advanced oncology treatments, including Karnataka's first Elekta Unit...
Read More
Shelter Pharma's Positive Reviews Drive Human Healthcare Growth
Shelter Pharma Ltd reports a steady stream of positive customer feedback for its human healthcare products, praising their effectiveness and quality. This consistent endorsement is boosting the company's brand credibility and long-term g...
Read More
Oxygenta Pharma Board to Review FY26 Results May 23, Past Financial Strain in Focus
Oxygenta Pharmaceutical Ltd's board will meet on May 23, 2026, to approve audited financial results for the fiscal year ending March 31, 2026. The approval is keenly watched due to the company's past financial difficulties.
Read More
Kwality Pharma Targets ₹650 Cr Revenue by FY27 with Capacity Expansion
Kwality Pharmaceuticals has set an ambitious revenue target of over ₹650 crore by FY27, a significant jump from ₹503 crore in FY26. This growth is underpinned by aggressive expansion in oncology, biologics, and hormone manufacturing capa...
Read More
Blue Jet Healthcare plans FY26 results call for May 25; FY25 revenue ₹568 crore
Blue Jet Healthcare will hold an investor call on May 25, 2026, to present its full-year financial results for the period ending March 31, 2026. This follows a strong FY25 where revenue reached ₹568 crore. Investors will focus on the com...
Read More
Kwality Pharma: Profit Soars 69% Amidst Rising Receivables
Kwality Pharmaceuticals reported strong Q4 and full FY26 results, with net profit up 69% and revenue climbing 36%. Its credit rating was upgraded by ICRA. A major concern remains its high level of trade receivables and long collection pe...
Read More
Apollo Hospitals Keeps Top 'AAA' Rating on ₹3,000 Crore Debt
ICRA has reaffirmed its highest credit ratings, 'ICRA AAA/Stable' and 'ICRA A1+', for Apollo Hospitals Enterprise Limited's ₹3,000 crore debt facilities. This confirms the company's strong financial health and market leadership, boosting...
Read More
Onesource Specialty Pharma Senior VP of Technical Development Resigns
Onesource Specialty Pharma Ltd announced the resignation of Prateek Gupta, its Senior Vice President & Head of Technical Development. His services conclude on May 15, 2026. This departure raises questions about continuity in the company'...
Read More
Niraj Shah Plans 6.22% Stake Buy in Speciality Medicines Ltd
Investor Niraj Rajnikant Shah plans to acquire 5,47,000 shares, or a 6.22% stake, in Speciality Medicines Ltd. The purchase is expected between March 30, 2026, and May 14, 2026, indicating strong investor confidence in the company.
Read More
Lupin's COPD Drug Revefenacin Gets Tentative FDA Approval
Lupin Ltd has received tentative approval from the US FDA for Revefenacin Inhalation Solution, a treatment for Chronic Obstructive Pulmonary Disease (COPD). This development targets a market segment similar to Mylan's Yupelri®, which pre...
Read More
SPARC Reports ₹1,761 Cr Q4 Profit Fueled by Voucher Sale, Net Worth Turns Positive
Sun Pharma Advanced Research (SPARC) reported a significant Q4 FY26 profit of ₹1,761.34 Cr, largely driven by a ₹1,840 Cr one-time gain from selling a USFDA Priority Review Voucher (PRV). The company's net worth is now positive, but conc...
Read More
Jubilant Pharmova Plans Investor Meetings May 25 Ahead of Q4 FY26 Results
Jubilant Pharmova Limited announced it will hold in-person meetings with institutional investors and analysts on May 25, 2026. The discussions will focus on the company's Q4'FY26 earnings presentation, scheduled for filing on May 22, 202...
Read More
Max Healthcare Buys 58% Kalinga Hospital Stake for ₹298 Cr
Max Healthcare Institute Ltd. acquired a controlling 58.28% stake in Kalinga Hospital Ltd. for ₹297.97 crore, making it a subsidiary. The move was financed by a ₹300 crore term loan, signaling Max Healthcare's expansion into new regions.
Read More